PDI Evista Lessons Learned: Firm Focuses On Smaller Contracts, No Baselines

PDI will focus on smaller contract sales opportunities in the 50-representative range following termination of the Evista promotion deal with Lilly, CEO Charles Saldarini said on a conference call Nov. 12

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet